2007

Details
Zugriffe: 5504

2007 (30 Publikationen)

  • Heiduschka P, Fietz H, Hofmeister S, Schultheiss S, Mack AF, Peters S, Ziemssen F, Niggemann B, Julien S, Bartz-Schmidt KU, Schraermeyer U; Tübingen Bevacizumab Study Group. Penetration of bevacizumab through the retina after intravitreal injection in the monkey. Invest Ophthalmol Vis Sci 2007; 48: 2814-2823 [IF 3.528]
  • Rohrbach JM, Grüb M, Szurman P. Einseitige, rezidivierende Trübung des Hornhautepithels. Ophthalmologe 2007; 223: 72-74 [IF 0.791]
  • Szurman P, Petermeier K, Grisanti S, Jaissle GB, Bartz-Schmidt KU. A new small-incision technique for injector implantation of transsclerally sutured foldable lenses. Ophthalmic Surg Lasers Imaging 2007; 38: 76-80 [IF 1.432]
  • Lüke M, Krott R, Warga M, Szurman P, Grisanti S, Bartz-Schmidt KU, Schneider T, Lüke C. Effects of the protein tyrosine kinase inhibitor genistein and taurine on retinal function in isolated superfused retina. Graefes Arch Clin Exp Ophthalmol 2007; 245 : 242-248 [IF 1.59]
  • Spitzer MS, Szurman P, Rohrbach JM, Aisenbrey S. Beidseitiges kongenitales Glaukom bei einem Kind mit Cutis marmorata telangiectatica congenita. Klin Monatsbl Augenheilkd 2007; 224: 66-69 [IF 0.576]
  • Gekeler F, Szurman P, Grisanti S, Weiler U, Claus R, Greiner TO, Volker M, Kohler K, Zrenner E, Bartz-Schmidt KU. Compound subretinal prostheses with extra-ocular parts designed for human trials: successful long-term implantation in pigs. Graefes Arch Clin Exp Ophthalmol 2007; 245: 230-241 [IF 1.59]
  • Jaissle GB, Szurman P, Völker M, Bartz-Schmidt KU. Epiretinal deposit of triamcinolone acetonide at the posterior pole after intravitreal injection. Ophthalmic Surg Lasers Imaging 2007; 38: 238-241 [IF 1.432]
  • Peters S, Heiduschka P, Julien S, Ziemssen F, Fietz H, Bartz-Schmidt KU; Tübingen Bevacizumab Study Group, Schraermeyer U. Ultrastructural findings in the primate eye after intravitreal injection of bevacizumab. Am J Ophthalmol 2007; 143: 995-1002 [IF 2.628]
  • Spitzer MS, Szurman P, Aisenbrey S, Rohrbach JM. Rapid development of band keratopathy of corneal graft after treatment with intracameral recombinant tissue plasminogen activator for postoperative fibrin reaction. Eur J Ophthalmol 2007; 17: 433-436 [IF 1.018]
  • Szurman P, Roters S, Grisanti S, Aisenbrey S, Rohrbach JM, Warga M, Gelisken F, Spitzer MS, Bartz-Schmidt KU. Primary silicone oil endotamponade in the management of severe intraocular foreign body injuries: an eight-year follow-up. Retina 2007; 27: 304-311 [IF 3.088]
  • Szurman P, Kaczmarek R, Jaissle GB, Grisanti S, Lüke M, Spitzer MS, Heide PE, Bartz-Schmidt KU. Influence of different purification techniques on triamcinolone yield and particle size spectrum. Graefes Arch Clin Exp Ophthalmol 2007; 245: 689-696 [IF 1.59]
  • Ziemssen F, Lüke M, Messias A, Beutel J, Tatar O, Zrenner E, Bartz-Schmidt KU; Tuebingen Bevacizumab Study Group. Safety monitoring in bevacizumab (Avastin) treatment: retinal function assessed by psychophysical (visual fields, colour vision) and electrophysiological (ERG/EOG) tests in two subgroups of patients. Int Ophthalmol 2007; 28: 101-109 []
  • Petermeier K, Szurman P. Subjektive und objektive Ergebnisse nach Implantation der apodisiert diffraktiven AcrySof ReSTOR. Ophthalmologe 2007; 104: 399-408 [IF 0.791]
  • Tatar O, Adam A, Shinoda K, Yoeruek E, Szurman P, Bopp S, Eckardt C, Bartz-Schmidt KU, Grisanti S. Influence of Verteporfin Photodynamic Therapy on Inflammation in Human Choroidal Neovascular Membranes secondary to Age-Related Macular Degeneration. Retina 2007; 27: 713-723 [IF 3.088]
  • Aisenbrey S, Bartz-Schmidt KU, Walter P, Hilgers RD, Ayertey H, Szurman P, Thumann G. Long-term follow-up of macular translocation with 360 degrees retinotomy for exudative age-related macular degeneration. Arch Ophthalmol 2007; 125: 1367-1372 [IF 2.984]
  • Peters S, Altvater A, Bopp S, Vonthein R, Szurman P, Spitzer MS, Warga M, Lüke M, Bartz-Schmidt KU, Grisanti S. Systematic evaluation of ICG and Trypan Blue related effects on ARPE-19 cells in vitro. Exp Eye Res 2007; 85: 880-889 [IF 2.651]
  • Spitzer MS, Sierra A, Yoeruek E, Wallenfels-Thilo B, Schraermeyer U, Spitzer B, Bartz-Schmidt KU, Szurman P. Comparative antiproliferative and cytotoxic profile of bevacizumab (AvastinTM), pegaptanib (MacugenTM) and ranibizumab (LucentisTM) on different ocular cells. Graefes Arch Clin Exp Ophthalmol 2007 ; 245 : 1837-1842 [IF 1.59]
  • Szurman P, Sierra A, Kaczmarek R, Jaissle GB, Wallenfels-Thilo B, Grisanti S, Lüke M, Bartz-Schmidt KU, Spitzer MS. Different biocompatibility of crystalline triamcinolone deposits on retinal cells in vitro and in vivo. Exp Eye Res 2007, 85: 44-53 [IF 2.651]
  • Yoeruek E, Spitzer MS, Tatar O, Aisenbrey S, Bartz-Schmidt KU, Szurman P. Safety profile of bevacizumab (Avastin®) on cultured human corneal cells. Cornea. 2007; 26: 977-982 [IF 1.776]
  • Yoeruek E, Jaegle H, Lüke M, Grisanti S, Warga M, Krott R, Spitzer MS, Tatar O, Bartz-Schmidt KU, Szurman P. Safety profile of a taurine containing irrigation solution (AcriPurRet®) in pars plana vitrectomy. Retina 2007; 27: 1286-1291 [IF 3.088]
  • Aisenbrey S, Ziemssen F, Völcker M, Gelisken F, Szurman P, Jaissle G, Grisanti S, Bartz-Schmidt KU. Intravitreal bevacizumab (Avastin) for occult choroidale neovascularization in age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 2007; 245: 941-948 [IF 1.59]
  • Jaissle GB, Szurman P, Rohrbach JM, Gelisken F, Bartz-Schmidt KU. A case of cutaneous melanoma metastatic to the vitreous cavity: Possible pathomechanism and review of the literature. Graefes Arch Clin Exp Ophthalmol 2007; 245: 733-740 [IF 1.59]
  • Heiligenhaus A, Szurman P, Heinz C. Aktuelle Kataraktchirurgie bei Uveitis im Kindesalter. Ophthalmologe 2007; 104: 572-576 [IF 0.791]
  • Peters S, Julien S, Heiduschka P, Grisanti S, Ziemssen F, Adler M, Schraermeyer U, Bartz-Schmidt KU; The Tuebingen Bevacizumab Study Group. Antipermeability and antiproliferative effects of standard and frozen bevacizumab on choroidal endothelial cells. Br J Ophthalmol 2007; 91: 827-831 [IF 2.689]
  • Szurman P, Heiligenhaus A, Hettlich HJ, Dick HB, Kohnen T. Kataraktchirurgie bei Uveitis im Kindesalter. Klin Monatsbl Augenheilkd 2007; 224: 532-537 [IF 0.576]
  • Aisenbrey S, Gelisken F, Szurman P, Bartz-Schmidt KU. Surgical treatment of peripapillary choroidal neovascularization. Br J Ophthalmol 2007; 91: 1027-1030 [IF 2.689]
  • Beutel J, Greulich L, Lueke M, Ziemssen F, Szurman P, Bartz-Schmidt KU, Grisanti S. Inner Limiting Membrane as membranous support in RPE sheet-transplantation. Graefes Arch Clin Exp Ophthalmol 2007; 245: 1469-1473 [IF 1.59]
  • Lüke M, Januschowski K, Warga M, Beutel J, Leitritz M, Gelisken F, Grisanti S, Schneider T, Lüke C, Bartz-Schmidt KU. Szurman P. The retinal tolerance to bevacizumab in co-application with a recombinant tissue plasminogen activator. Br J Ophthalmol 2007; 91: 1077-1082 [IF 2.689]
  • Gelisken F, Voelker M, Schwabe R, Besch D, Aisenbrey S, Szurman P, Grisanti S, Herzau V, Bartz-Schmidt KU. Full Macular Translocation versus Photodynamic Therapy with Verteporfin in Treatment of Neovascular Age-related Macular Degeneration: 1 Year Results of a prospective, controlled, randomised Pilot-Trial (FMT-PDT). Graefes Arch Clin Exp Ophthalmol 2007, 245: 1085-1095 [IF 1.59]
  • Lüke M, Szurman P, Schneider T, Lüke C. Effects of the phosphodiesterase type V inhibitor sildenafil on human retinal function in vitro. Graefes Arch Clin Exp Ophthalmol 2007; 245: 1211-1215 [IF 1.59]

2008

Details
Zugriffe: 5456

2008 (23 Publikationen)

  • Spitzer MS, Ziemssen F, Yoeruek E, Petermeier K, Aisenbrey S, Szurman P. Efficacy of intravitreal bevacizumab in treating postoperative pseudophakic cystoid macular edema. J Cataract Refract Surg 2008; 34: 70-75 [IF 2.508]
  • Tatar O, Shinoda K, Kaiserling E, Pertile G, Eckardt C, Mohr A, Yoeruek E, Szurman P, Bartz-Schmidt KU, Grisanti S. Early effects of triamcinolone acetonide on vascular endothelial growth factor and endostatin in human choroidal neovascularization. Arch Ophthalmol 2008; 126: 193-199 [IF 3.242]
  • Yoeruek E, Spitzer MS, Tatar O, Biedermann T, Grisanti S, Lüke M, Bartz-Schmidt KU, Szurman P. Toxic effects of recombinant tissue plasminogen activator on human corneal endothelial cells. Invest Ophthalmol Vis Sci 2008; 49: 1392-1397 [IF 3.528]
  • Jaissle GB, Ulmer A, Henke-Fahle S, Fierlbeck G, Bartz-Schmidt KU, Szurman P. Suppression of melanoma-associated neoangiogenesis by bevacizumab. Arch Dermatol 2008; 144: 525-527 [IF 3.402]
  • Yoeruek E, Szurman P, Tatar O, Weckerle P, Wilhelm H. Anterior ischemic optic neuropathy due to giant cell arteritis with normal inflammatory markers. Graefes Arch Clin Exp Ophthalmol 2008; 246: 913-915 [IF 1.770]
  • Lüke M, Januschowski K, Beutel J, Lüke C, Grisanti S, Peters S, Kirchhof B, Bartz-Schmidt KU, Szurman P. The electrophysiological effects of Brilliant Blue G in the model of the isolated perfused vertebrate retina. Graefes Arch Clin Exp Ophthalmol 2008; 246: 817-822 [IF 1.770]
  • Feudner EM, Gelisken F, Szurman P. Asymmetrisch ausgeprägte kristalline retinale Ablagerungen. Ophthalmologe 2008; 105: 384-388 [IF 1.133]
  • Yoeruek E, Ziemssen F, Henke-Fahle S, Tatar O, Tura A, Grisanti S, Bartz-Schmidt KU, Szurman P. Tübingen Bevacizumab Study Group: Safety, penetration and efficacy of topically applied bevacizumab: evaluation of eyedrops in corneal neovascularization after chemical burn. Acta Ophthalmol Scand 2008; 86: 322-387 [IF 2.138]
  • Bartz-Schmidt KU, Szurman P, Wong D, Kirchhof B. Neue Entwicklungen in der chirurgischen Therapie der rhegmatogenen Ablatio retinae. Ophthalmologe 2008; 105:27-36 [IF 1.133]
  • Ziemssen F, Zhu Q, Peters S, Grisanti S, El Wardani M, Szurman P, Bartz-Schmidt KU; Tuebingen Bevacizumab Study Group, Ziemssen T. Intensified monitoring of circadian blood pressure and heart rate before and after intravitreous injection of bevacizumab: preliminary findings of a pilot study. Int Ophthalmol 2008; 28: 101-109 []
  • Yoeruek E, Deuter CM, Szurman P, Tatar O, Zierhut M. Varicella-Zoster-Virus-assoziierte Skleromalazie. Ophthalmologe 2008; 105: 480-484 [IF 1.133]
  • Spitzer MS, Szurman P, Bartz-Schmidt KU. Correspondence: Intravitreal bevacizumab in postoperative pseudophakic cystoid macular edema: Does it really work? J Cataract Refract Surg 2008; 34: 880-881 [IF 2.508]
  • Szurman P. August consultation 4. J Cataract Refract Surg 2008; 34: 1234 [IF 2.508]
  • Jaissle GB, Bartz-Schmidt KU, Szurman P. Opticus-Atrophie nach epiretinalen Traimcinolon-Ablagerungen nach ILM-Peeling. Ophthalmologe 2008; 205: 575-577 [IF 1.133]
  • Tatar O, Yoeruek E, Szurman P, Bartz-Schmidt KU; Tübingen Bevacizumab Study Group, Adam A, Shinoda K, Eckardt C, Boeyden V, Claes C, Pertile G, Scharioth GB, Grisanti S. Effect of bevacizumab on inflammation and proliferation in human choroidal neovascularization. Arch Ophthalmol 2008;126: 782-790 [IF 3.242]
  • Lüke M, Januschowski K, Beutel J, Warga M, Grisanti S, Peters S, Schneider T, Lüke C, Bartz-Schmidt KU, Szurman P. The effects of triamcinolone crystals on retinal function in a model of isolated perfused vertebrate retina. Exp Eye Res 2008; 87: 22-29 [IF2.579]
  • Rohrbach JM, Szurman P, Bartz-Schmidt KU. 100 Jahre Universitäts-Augenklinik Tübingen. Klin Monatsbl Augenheilkd 2008; 225: 975-982 [IF 0.576]
  • Besch D, Sachs H, Szurman P, Gülicher D, Wilke R, Reinert S, Zrenner E, Bartz-Schmidt KU, Gekeler F. Extraocular surgery for implantation of an active subretinal viusal prosthesis with external connections: feasibility and outcome in seven patients; Br J Ophthalmol 2008; 92: 1361-1368 [IF 2.859]
  • Spitzer MS, Ziemssen F, Gelisken F, Bartz-Schmidt KU, Szurman P. Treatment of age-related macular degeneration: Focus on ranibizumab. Clin Ophthalmol 2008; 2: 1-14 [IF 1.031]
  • Spitzer MS, Yoeruek E, Kaczmarek RT, Sierra A, Aisenbrey S, Grisanti S, Bartz-Schmidt KU, Szurman P. Sodium hyaluronate gels as a drug release system for corticosteroids: Release kinetics and antiproliferative potential for glaucoma surgery. Acta Ophthalmol Scand 2008; 8: 842-848 [IF 2.138]
  • Spitzer MS, Batumba NH, Chirambo T, Kayange P, Szurman P. Ocular surface squamous neoplasia as first apparent manifestation of HIV infection in Malawi. Clin Exp Ophthalmol 2008; 36: 422-425 [IF 1.347]
  • Yoeruek E, Spitzer MS, Saygili O, Tatar O, Biedermann T, Yoeruek E, Bartz-Schmidt KU, Szurman P. Comparison of in vitro safety profiles of Vancomycin and cefuroxime on human corneal endothelial cells for intracameral use. J Cataract Refract Surg 2008; 34; 2139-2145 [IF 2.508]
  • Zhu Q, Ziemssen F, Henke-Fahle S, Tatar O, Szurman P, Aisenbrey S, Schneiderhan-Marra N, Xu X, Grisanti S. Vitreous levels of bevacizumab and vascular endothelial growth factor-A in patients with choroidal neovascularization. Ophthalmology 2008; 115; 1750-1755 [IF 5.296]

2009

Details
Zugriffe: 5701

2009 (17 Publikationen)

  • Jaissle GB, Leitritz M, Gelisken F, Ziemssen F, Bartz-Schmidt KU, Szurman P. One-year results after intravitreal bevacizumab therapy for macular edema secondary to branch retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol. 2009; 247; 27-33 [IF 2.102]
  • Tatar O, Adam A, Shinoda K, Kaiserling E, Boeyden V, Claes C, Eckardt C, Eckert T, Pertile G, Scharioth GB, Yoeruek E, Szurman P, Bartz-Schmidt KU, Grisanti S. Early effects of intravitreal triamcinolone acetonide on inflammation and proliferation in human choroidal neovascularization. Arch Ophthalmol 2009; 127: 275-281 [IF 3.859]
  • Neuhann IM, Neuhann TF, Szurman P, Koerner S, Rohrbach JM, Bartz-Schmidt KU. Clinicopathological correlation of 3 patterns of calcification in a hydrophilic acrylic intraocular lens. J Cataract Refract Surg 2009; 35: 593-597 [IF 2.745]
  • Jaissle GB, Ulmer A, Henke-Fahle S, Aisenbrey S, Fierlbeck G, Bartz-Schmidt KU, Szurman P. Intraokulares Bevacizumab als palliative Therapie bei Melanommetastasen-assoziiertem rubeotischen Sekundärglaukom. Klin Monatsbl Augenheilkd 2009; 226: 70-72 [IF 0.576]
  • Tatar O, Shinoda K, Kaiserling E, Claes C, Eckardt C, Eckert T, Boeyden V, Pertile G, Yoeruek E, Szurman P, Bartz-Schmidt KU, Grisanti S. Implications of bevacizumab on vascular endothelial growth factor and endostatin in human choroidal neovascularization. Br J Ophthalmol 2009; 93: 159-165 [IF 2.917]
  • Peters S, Tatar O, Spitzer MS, Szurman P, Aisenbrey S, Lüke M, Adam A, Yoeruek E, Grisanti S. Analysis of the neuronal marker protein gene product 9.5 in internal limiting membranes after indocyanine-green assisted peeling. Retina 2009; 29: 243-247 [IF 3.478]
  • Spitzer MS, Kaczmarek RT, Yoeruek E, Petermeier K, Wong D, Heimann H, Jaissle GB, Bartz-Schmidt KU, Szurman P. The distribution, release kinetics and biocompatibility of triamcinolone injected and dispersed in silicone oil. Invest Ophthalmol Vis Sci 2009; 50: 2337-2343 [IF 3.582]
  • Feudner EM, Engel C, Neuhann IM, Petermeier K, Bartz-Schmidt KU, Szurman P. Virtual reality training improves wet-lab performance of capsulorhexis: results of a randomized, controlled study. Graefes Arch Clin Exp Ophthalmol 2009; 247: 955-963 [IF 2.102]
  • Yoeruek E, Saygili O Spitzer MS, Tatar O, Bartz-Schmidt KU, Szurman P. Human anterior lens capusle as a carrier matrix for cultivated human corneal endothelial cells. Cornea 2009; 28: 416-420 [IF 1.853]
  • Frank C, Szurman P, Peters S, Zierhut M, Spitzer MS. Spätes Rezidiv einer Spender-assoziierten Endophthalmitis durch Candida glabrata nach Keratoplastik. Klin Monatsbl Augenheilkd 2009; 26: 510-511 [IF 0.576]
  • Kaczmarek R, Szurman P, Misiuk-Hojło M, Grzybowski A. Antiproliferative effects of preservative-free triamcinolone acetonide on cultured human retinal pigment epithelial cells. Med Sci Monit 2009; 15: 227-231 [IF 1.514]
  • Szurman P, Frank C, Kaczmarek RT, Spitzer MS. Glaskörperersatz als Möglichkeit zur protrahierten Freisetzung von Medikamenten im Glaskörper. Klin Monatsbl Augenheilkd 2009; 226: 718-724 [IF 0.576]
  • Petermeier K, Gekeler F, Spitzer MS, Szurman P. Implantation of the multifocal ReSTOR apodized diffractive intraocular lens in adult anisometropic patients with mild to moderate amblyopia. Br J Ophthalmol 2009; 93: 1269-1301 [IF 2.917]
  • Petermeier K, Gekeler F, Messias A, Spitzer MS, Haigis W, Szurman P. Intraocular lens power calculation in highly myopic eyes implanted with the Alcon AcrySof® MA60MA. J Cataract Refract Surg 2009; 35: 1575-1581 [2.745]
  • Lüke M, Januschowski K, Lüke J, Peters S, Wirtz N, Yörük E, Lüke Ch, Bartz-Schmidt KU, Grisanti S, Szurman P. The effects of ranibizumab (Lucentis®) on retinal function in isolated perfused vertebrate retina. Br J Ophthalmol 2009; 2009; 93: 1396-1400 [IF 2.917]
  • Spitzer MS; Chirambo T, Kayange P, Szurman P, Yoeruek E, Bartz-Schmidt KU, Batumba HN. Der Einfluss der HIV-Pandemie auf die Inzidenz maligner Augentumoren im südlichen Malawi (Blantyre). Ophthalmologe 2009; 106: 813-818 [IF 1.133]
  • Petermeier K, Messias A, Gekeler F, Spitzer MS, Szurman P. Outcomes of the AcrySof ReSTOR® IOL in myopes, emmetropes, and hyperopes. J Refract Surg 2009; 25: 1103-1109 [IF 1.914]

Kontakt

Callcenter:
06897 / 574-1121

E-Mail-Formular

Notfallambulanz (Pforte, außerhalb der Callcenter-Sprechzeiten):
06897 / 574-0

Privatambulanz (Chefarzt-Sekretariat):
06897 / 574-1119

Adresse:
Augenklinik Sulzbach, An der Klinik 10
66280 Sulzbach

Anfahrt

Kontakt

Logo KHERI augenklinik saar

KTQ Zertifikat

Wussten Sie schon?

Unser hohes Maß an Qualität wurde uns als erster Klinik im Saarland offiziell zertifiziert. Das KTQ-Siegel steht für Patientenorientierung, geprüfte Qualität und Sicherheit.